Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing

Next Previous
Trial Profile

A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms A.R.R.O.W.; ARROW
  • Sponsors Amgen; Ono Pharmaceutical; Onyx Pharmaceuticals

Most Recent Events

  • 01 Oct 2022 Results of post-hoc pooled analysis assessing cardiovascular risk factors and cardiovascular disease data from four clinical studies: ASPIRE, ARROW, FOCUS, ENDEAVOR published in the Clinical Lymphoma, Myeloma & Leukemia
  • 22 Nov 2019 According to an Ono Pharmaceutical media release, the company has received an approval for KYPROLIS for Intravenous Injection 10 mg and 40 mg ("Kyprolis"), in Japan for additional dosage and administration in patients with relapsed or refractory multiple myeloma, for a partial change in approved items of the manufacturing and marketing approval.
  • 12 Sep 2019 According to an Amgen media release, data from this trial will be presented at the 17th International Myeloma Workshop (IMW) 2019 in Boston, Sept. 12-15, 2019.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top